MissionIR Articles

Seeks patent on new therapy for drug that employs concentrations of THC Data for drug candidate IGC-AD1 finds that it reduces buildup of ‘senior plaque’ without causing death of neurons, which can lead to memory…

Product portfolio to include drugs and supplements Faster monetization of lead Alzheimer’s candidate as supplement Market valuation poised to soar It should come as no surprise to discover that the medical cannabis dispensary product line…

Four drug candidates in the pipeline Potential sales of Alzheimer’s drugs run to billions Hyalolex heading for clinical trials India Globalization Capital, Inc. (NYSE MKT: IGC) is racing ahead with its preparation of medical trials…

IGC is the only publicly traded cannabis stock with patent filings for treating Alzheimer’s disease Company has a first-mover advantage in phytocannabinoid-based combination therapy Alzheimer’s is America’s most expensive disease, costing the country an estimated…

More than 5.3 million people in the U.S. have Alzheimer’s disease, which has no effective cure or substantial treatment India Globalization Capital’s IGC-ADI drug candidate targets proteins associated with the buildup of lesions in the…

Hyalolex for Alzheimer’s and other cannabis-based drugs for pain, epilepsy, and more are raising the market valuation growth potential for IGC Phytocannabinoids target protein receptors in the brain, peripheral nervous system and other parts of…

Alzheimer’s is America’s most expensive disease, with a new diagnosis every 66 seconds IGC’s unique use of marijuana extracts in combination therapy for potential Alzheimer’s breakthrough shows promise Low market cap could make IGC a…

Alzheimer’s is a leading cause of dementia in adults in the United States IGC’s cannabis-based drug may reverse the buildup of beta-amyloid plaque Hyalolex and other phytocannabinoid-based drugs are fueling potential for the company’s market…

Core operations transitioned to phytocannabinoid-based therapies Four trial candidates targeting chronic pain, Alzheimer’s and other conditions Unique approach combining existing therapies with cannabinoids India Globalization Capital, Inc. (NYSE MKT: IGC) is developing disruptive new pharmaceutical…

India Globalization Capital recently acquired exclusive patent rights for the use of low-dose THC as a potential therapeutic agent for Alzheimer’s disease No other publicly traded cannabis pharmaceutical company has a patent filing for a…

IGC purchased exclusive rights to USF patent focused on preventing amyloid-beta plaques from aggregating on neurons Company plans to pursue clinical trials related to this patent on path to FDA approval In 2017, direct costs…